Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Autori
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2025

This article is not included in any systematic review

Loading references information
This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The study aims to establish the maximally tolerated dose (MTD) and recommended Phase II dose (RP2D) while also exploring efficacy outcomes, including progression-free survival (PFS) and overall survival (OS).
Epistemonikos ID: ba30db39a3078312fc50cf7a1fbceac8aa1ebece
First added on: Apr 05, 2025